Skip to search formSkip to main contentSkip to account menu

LY 303366

Known as: LY-303366, LY303366 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2002
Review
2002
  • D. Denning
  • The Journal of antimicrobial chemotherapy
  • 2002
  • Corpus ID: 7562690
The echinocandins represent the first new antifungal drug class introduced for more than 15 years. They inhibit the synthesis of… 
Highly Cited
2000
Highly Cited
2000
ABSTRACT The postantifungal effect (PAFE) of fluconazole, MK-0991, LY303366, and amphotericin B was determined against isolates… 
Highly Cited
1998
Highly Cited
1998
ABSTRACT The in vitro antifungal activities of SCH56592, MK-0991, and LY303366 against 83 isolates of Acremonium strictum… 
Highly Cited
1998
Highly Cited
1998
ABSTRACT This study was designed to examine the effects of antifungal carryover, agitation, and starting inoculum on the results… 
Highly Cited
1998
Highly Cited
1998
ABSTRACT LY303366 is a novel antifungal echinocandin with excellent in vitro activity against Aspergillus spp. We compared four… 
Highly Cited
1997
Highly Cited
1997
LY303366 is a new semisynthetic echinocandin derivative with potent, broad-spectrum fungicidal activity. We investigated the in… 
Review
1994
Review
1994
The discovery of antifungal agents that possess selective toxicity against the eukaryotic fungal cell remains an important… 
Highly Cited
1994
Highly Cited
1994
The lipopeptide antifungal agents, echinocandins, papulacandins, and pneumocandins, kill Candida albicans by inhibiting glucan…